Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage III follicular thyroid cancer
Trial Type:  Treatment
Trial Status:  Active
Results 1-24 of 24 for your search:
Start Over
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: NCCCTS13-671, 1410650-1,2, NCT02418247
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00065, EudraCT 2013-000423-14, NCT01843062
Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: B-1403/242-006, NCT02112370
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00041909, WCI1777-09, NCT01270321
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-12064, NCI-2012-01700, NCCNGSK20008, NCT01723202
Nintedanib(BIBF1120) in Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1209, 2012-004295-19, NCT01788982
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00554, 2012C0101, RU241210I, OSU 12154, 9312, N01CM00039, N01CM00070, N01CM00071, N01CM00099, P30CA016058, NCT01811212
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PAZOTHYR, 2012-003162-41, NCT01813136
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: UC-0105/1303, 2013-000885-13, NCT02034981
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 28313, NCT02041260
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 410-30610-258, NCT02084732
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A091302, U10CA180821, NCI-2014-00623, NCT02143726
A Multicenter Phase II Pilot Open Label
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-748, NCT01830504
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UC-0105/1401, 2014 001225 33, NCT02304809
Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KO-TIP-001, NCT02383927
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1162, NA_00048646, NCT01438554
EVESOR: a Phase 1 Trial of Everolimus and Sorafenib
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-716, NCT01932177
Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HNO-FDG-FU, NCT00180245
Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma
Phase: No phase specified
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 to 45
Sponsor: Other
Protocol IDs: SMMU-2-2009-3, NCT00993837
Measuring Patient Expectations for Thyroid Surgery
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-087, NCT01412762
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: UKW-NUK-I-124, NCT01704586
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-031, NCT02145143
Start Over